In previous studies of delayed reinforcement, response rate has been found to vary inversely with the response-reinforcer interval. However, in all of these studies the independent variable, response-reinforcer time, was confounded with the number of reinforcers presented in a fixed period of time (reinforcer frequency). In the present study, the frequency of available reinforcers was held constant, while temporal separation between response and reinforcer was independently manipulated. A repeating time cycle, T, was divided into two alternating time periods, t(D) and t(Delta). The first response in t(D) was reinforced at the end of the prevailing T cycle and extinction prevailed in t(Delta). Two placements for t(D) were defined, an early t(D) placement in which t(D) precedes t(Delta) and a late t(D) placement in which t(D) follows t(Delta). The duration of the early and late t(D) was systematically decreased from 30 seconds (i.e., t(D) = T) to 0.1 second. Manipulation of t(D) placement and duration controlled the temporal separation between response and reinforcement, but it did not affect the frequency of programmed reinforcers, which was 1/T. The results show that early and late t(D) placements of equal duration have similar overall effects upon response rate, reinforcer frequency, responses per reinforcer, and obtained response-reinforcer temporal separation. A stepwise regression analysis using log response rate as the dependent variable showed that the obtained delay was a significant first-step variable for six of eight subjects, with obtained reinforcer frequency significant for the remaining two subjects.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1348028 | PMC |
http://dx.doi.org/10.1901/jeab.1984.41-143 | DOI Listing |
Clin Cancer Res
January 2025
Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
Purpose: Mesothelin (MSLN) is highly expressed in high grade serous/ endometrioid ovarian cancers (HGOC). Anetumab ravtansine (AR) is an antibody drug conjugate directed at MSLN antigen with a tubulin polymerization inhibitor. We assessed safety, activity and pharmacokinetics of the combination AR/bevacizumab (Bev) (ARB) versus weekly paclitaxel (wP)/Bev (PB) in patients with platinum resistant/refractory HGOC (prrHGOC).
View Article and Find Full Text PDFClin Cancer Res
January 2025
Istituti Fisioterapici Ospitalieri, Italy.
Background: The role of activating alterations in the MAPK pathway in predicting immunotherapy efficacy in lung squamous cell carcinoma (LSCC) patients is largely unknown. The aims of the randomized, phase II SQUINT trial were to assess the efficacy of nivolumab plus ipilimumab (NI) versus platinum-based chemotherapy plus nivolumab (N-CT) and to identify clinically available biomarkers of response to immunotherapy in patients with advanced or metastatic LSCC.
Methods: SQUINT was an open-label, randomized, parallel, non-comparative, phase II trial of NI versus N-CT in chemo-naïve, metastatic or recurrent LSCC adult patients.
Neurosurg Rev
January 2025
Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, 45# Changchun Street, Xicheng District, Beijing, China.
Chordoma is a rare malignant tumor with a higher incidence in males than in females. There is an increasing number of clinical studies related to tyrosine kinase inhibitors (TKIs), yet the efficacy and safety of different drugs vary. In this single-arm meta-analysis evaluating the efficacy and safety of TKIs for chordoma treatment, 12 studies involving 365 patients were analyzed.
View Article and Find Full Text PDFInt J Colorectal Dis
January 2025
Internal Medicine, Jilin Cancer Hospital, Changchun, China.
Purpose: This phase II study is designed to evaluate the combination therapy involving suvemcitug and envafolimab with FOLFIRI in microsatellite-stable or mismatch repair-proficient (MSS/pMMR) colorectal cancer (CRC) in the second-line treatment setting.
Methods: This study is a non-randomized, open-label prospective study comprising multiple cohorts (NCT05148195). Here, we only report the data from the CRC cohort.
Support Care Cancer
January 2025
Department of Medicine, Faculty of Medicine, Srinakharinwirot University, Nakhon Nayok, Thailand.
Background: Malnutrition affects the prognosis and response to treatment in cancer patients. There is no gold standard for nutritional assessment in patients with hepatocellular carcinoma (HCC). This study aimed to compare Patient-Generated Subjective Global Assessment (PG-SGA) and Mini Nutritional Assessment (MNA) in predicting mortality in HCC patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!